Scarica l'app Stockscreener
870.37
3.35%
28.19
Dopo l'orario di chiusura:
867.30
-3.07
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$842.18
Aprire:
$839.52
Volume 24 ore:
6.96M
Relative Volume:
1.82
Capitalizzazione di mercato:
$827.20B
Reddito:
$40.86B
Utile/perdita netta:
$8.37B
Rapporto P/E:
94.09
EPS:
9.25
Flusso di cassa netto:
$-2.28B
1 W Prestazione:
+5.73%
1M Prestazione:
+13.76%
6M Prestazione:
+9.73%
1 anno Prestazione:
+23.45%
Intervallo 1D:
$835.61
$887.74
Intervallo di 1 settimana:
$801.75
$887.74
Portata 52W:
$707.02
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
870.37 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.17 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.51 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.97 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.05 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly and Co (LLY) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid - Morningstar
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat - Morningstar
Why Eli Lilly Shrugged Off its Weight-Loss Disappointment - Investor's Business Daily
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript - The Motley Fool
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight (LLY) - Seeking Alpha
Eli Lilly, Novo Nordisk sold more than $40 billion in GLP-1 drugs in 2024 - Sherwood News
A Closer Look at Eli Lilly's Options Market Dynamics - Benzinga
Eli Lilly and Company (NYSE:LLY) Trading Up 4.1%Should You Buy? - MarketBeat
What Are Wall Street Analysts' Target Price For Eli Lilly Stock? - Barchart
Lilly reassures investors that weight-loss drug demand is strong, shares rise - Reuters
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound - FiercePharma
Eli Lilly annual profit outlook tops expectations; stock gains - Investing.com
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - 21 Alive News
Lilly’s profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales - WISH TV Indianapolis, IN
Why Eli Lilly Stock Popped on Thursday - The Motley Fool
Eli Lilly Stock Rises After Profit, Outlook Top Expectations - Kiplinger's Personal Finance
Lilly’s profit forecast bring investors some relief amid Zepbound miss - PharmaLive
Lilly reports robust Q4, full-year earnings - Inside INdiana Business
Market movers: Ford, Peloton, Skyworks Solutions, Eli Lilly... - Proactive Investors USA
Eli Lilly’s Net Income Doubles And Its Revenue Grows 45% - Baystreet.ca
Eli Lilly revenue misses expectations despite strong growth in Mounjaro, Zepbound - Proactive Investors USA
Eli Lilly (LLY) Stock Rises on Strong Q4 Earnings and Bullish 2025 Outlook – market - HPBL
Zepbound sales keep soaring, even as weight loss drug growth slows - Quartz
Eli Lilly Full-Year Earnings Meet Expectations Amid GLP-1 Inventory Challenges – market - HPBL
Eli Lilly (LLY) Reports Blockbuster Q4 Revenue Growth Fueled by Mounjaro and Zepbound Sales - HPBL
Eli Lilly expects to beat profit forecasts on obesity drug demand - Financial Times
Eli Lilly forecasts 2025 profit growth after recent weight-loss drug worries - The Globe and Mail
Weight-loss drugs swell revenues at Eli Lilly - ShareCast
Eli Lilly Posts Mixed Q4 Results; Fiscal 2025 Guidance Reaffirmed - Yahoo Finance UK
Lilly issues 2025 profit view as it steers for revenue boost - MSN
Eli Lilly: 4th quarter consensus beaten -February 06, 2025 at 08:11 am EST - Marketscreener.com
Lilly Profit View ‘Enough to Pacify Investors’ After Sales Miss - BNN Bloomberg
Eli Lilly CEO reveals latest developments in Alzheimer's research - Fox Business
Eli Lilly Reports Q4 2024 Earnings: EPS at $4.88, Revenue Hits $13.53 Billion, Missing Analyst Estimates - GuruFocus.com
Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs - Yahoo Finance UK
Lilly forecasts 2025 profit above estimates on weight-loss drug strength - Business Standard
Eli Lilly stock rises on Q4 2024 beat (update) (LLY:NYSE) - Seeking Alpha
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines - Yahoo Finance
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds Expectations - Investing.com Canada
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected - CNBC
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments - TipRanks
Eli Lilly Reports Q4 Worldwide Mounjaro Revenue Increased 60% To $3.53 Billion -February 06, 2025 at 07:15 am EST - Marketscreener.com
Eli Lilly’s Q4 2024 Revenue Surges by 45% to $13.53 Billion - The Tokenist
Eli Lilly Q4 Non-GAAP Earnings, Revenue Increase; 2025 Outlook Issued -February 06, 2025 at 07:10 am EST - Marketscreener.com
Lilly says Mounjaro and Zepbound contributed to big revenue boost - MarketWatch
Eli Lilly’s Full-Year Profit Views in Line After Recent Misses - Bloomberg
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short - CNBC
Lilly: Q4 Earnings Snapshot -February 06, 2025 at 06:57 am EST - Marketscreener.com
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets - Marketscreener.com
Bernstein reiterates Eli Lilly stock Outperform with $1,100 target - Investing.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.68%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):